Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Amicus Therapeutics Carves Out Gene Therapy Portfolio, Reduces Upside Optionality
04:02pm, Wednesday, 06'th Oct 2021
Amicus Therapeutics announced the formation of Caritas Therapeutics, consisting of Amicus' gene therapy portfolio.
New York, New York--(Newsfile Corp. - October 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Amicus Therapeutics, Inc. (NASDAQ: F
Amcius (FOLD) to Spin-Off Gene Therapy Arm, Form New Firm With ARYA
02:10pm, Thursday, 30'th Sep 2021
Amicus (FOLD) plans to separate its gene therapy business into a new company formed in alliance with ARYA Sciences Acquisition Corp.
Amicus stock is up 5%, the day after announcing plans to sell its gene therapy business
08:18am, Thursday, 30'th Sep 2021
Shares of Amicus Therapeutics Inc. FOLD, -5.11% were up 5.6% in premarket trading on Thursday, the day after the company announced a deal to sell its gene therapy business to ARYA Sciences Acquisition
Amicus Therapeutics, Inc. (FOLD) on Formation of Caritas Therapeutics Conference Call (Transcript)
07:29pm, Wednesday, 29'th Sep 2021
Amicus Therapeutics, Inc. (FOLD) on Formation of Caritas Therapeutics Conference Call (Transcript)
Perceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy Business
09:26am, Wednesday, 29'th Sep 2021
Amicus Therapeutics Inc (NASDAQ: FOLD) has agreed to spin off its gene therapy business to Sciences Acquisition Corp IV (NASDAQ: ARYD) and launch genetic medicine company Caritas Therapeutics In
Why Are Amicus Therapeutics Shares Trading Higher Today?
08:47am, Wednesday, 29'th Sep 2021
The FDA has accepted for review Amicus Therapeutics Inc's (NASDAQ: FOLD) Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat for AT-GAA. Al
Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Fundin
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2021
07:00am, Friday, 03'rd Sep 2021
PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2021 Results - Earnings Call Transcript
12:34am, Friday, 06'th Aug 2021
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2021 Results - Earnings Call Transcript
Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates
09:54am, Thursday, 05'th Aug 2021
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 9.52% and 8.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
07:00am, Wednesday, 04'th Aug 2021
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Vir
Amicus's Fabry Disease Medicine Gets European Approval For Use In Adolescents
08:50am, Monday, 02'nd Aug 2021
The European Commission has approved Amicus Therapeutics Inc (NASDAQ: FOLD) Galafold (migalastat) for use in adolescents with Fabry disease who have an amenable mutation. Galafold is already appr
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
07:00am, Monday, 02'nd Aug 2021
Galafold® is the First and Only Oral Therapy Approved in the EU for the Long-term Treatment of Adolescents with Fabry Disease Aged 12 years and older with an Amenable Mutation Galafold® is the First
Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
07:00am, Tuesday, 27'th Jul 2021
PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 5, 2021 at 8:
